SCHEMBL20840563

SCHEMBL20840563

CNc1cc(F)c(F)c2cccnc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 6/20 0.58
GLO1 Q04760 1/20 0.41
KDM4E B2RXH2 8/20 0.41
L3MBTL1 Q9Y468 6/20 0.41
MPI P34949 1/20 0.41
NPC1 O15118 2/20 0.40
HSP90AA1 P07900 1/20 0.40
GRM4 Q14833 2/20 0.40
CCR1 P32246 1/20 0.38
CCR8 P51685 1/20 0.38
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10510901 0.78 SLC40A1 (0.51) SLC40A1KDM4EL3MBTL1MPINPC1
SCHEMBL22797153 0.76 GLO1 (0.49) SLC40A1GLO1KDM4EL3MBTL1MPI
SCHEMBL19799374 0.74 MEN1 (0.51) SLC40A1GLO1L3MBTL1NPC1HSP90AA1
SCHEMBL30925419 0.74 SLC40A1 (0.80) SLC40A1KDM4ENPC1HSP90AA1ALDH1A1
SCHEMBL11973836 0.74 SLC40A1 (1.00) SLC40A1GLO1KMT2ATDP1MEN1
SCHEMBL24715868 0.74 KDM4E (0.62) SLC40A1KDM4EL3MBTL1MPINPC1
SCHEMBL11973547 0.74 MEN1 (0.51) SLC40A1KDM4EL3MBTL1MPINPC1
SCHEMBL18280047 0.74 SLC40A1 (0.48) SLC40A1KDM4EL3MBTL1MPINPC1
SCHEMBL24715869 0.73 NSD2 (0.48) SLC40A1KDM4EL3MBTL1MPINPC1
SCHEMBL28517529 0.71 HSP90AA1 (0.58) SLC40A1KDM4EL3MBTL1MPINPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11396501-B2 Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) 2022-07-26 US disclosed
EP-3687540-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CGeneTech (Suzhou, China) Co., Ltd. (CN) 2020-08-05 EP disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2020-07-30 US disclosed
WO-2019060860-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-03-28 WO disclosed
WO-2019060860-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2019-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11396501-B2 Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same CXCR4, CXCL12, CXCR1 SLC40A1 2226/4885GLO1 4883/4885KDM4E 4466/4885
US-20200239439-A1 HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME CXCR4, CXCL12, CXCR1 SLC40A1 2226/4885GLO1 4883/4885KDM4E 4466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.